BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...Emergent BioSolutions Inc. (NYSE:EBS) Adapt Pharma Ltd. 8/28/18 $575 (B) $100 $735 10x Genomics Inc. Epinomics Inc....
BioCentury | Apr 28, 2017
Finance

1Q17 public-private partnership roundup

...Inc. Boston University Cancer Research Institute Cidara Therapeutics Inc. Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Engineering and Physical Sciences Research Council Epinomics Inc. Forge...
BioCentury | Feb 17, 2017
Company News

Epinomics, Stanford deal

...Epinomics’ immune intelligence technology to improve outcomes and reduce adverse events in immune-oncology clinical trials. Epinomics...
...for future testing. Epinomics Inc. , Menlo Park, Calif. Stanford University , Stanford, Calif. Business: Cancer Nora Weintraub Epinomics Inc. Parker...
Items per page:
1 - 3 of 3
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...Emergent BioSolutions Inc. (NYSE:EBS) Adapt Pharma Ltd. 8/28/18 $575 (B) $100 $735 10x Genomics Inc. Epinomics Inc....
BioCentury | Apr 28, 2017
Finance

1Q17 public-private partnership roundup

...Inc. Boston University Cancer Research Institute Cidara Therapeutics Inc. Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Engineering and Physical Sciences Research Council Epinomics Inc. Forge...
BioCentury | Feb 17, 2017
Company News

Epinomics, Stanford deal

...Epinomics’ immune intelligence technology to improve outcomes and reduce adverse events in immune-oncology clinical trials. Epinomics...
...for future testing. Epinomics Inc. , Menlo Park, Calif. Stanford University , Stanford, Calif. Business: Cancer Nora Weintraub Epinomics Inc. Parker...
Items per page:
1 - 3 of 3